T
Thomas Stuckey
Researcher at Cone Health
Publications - 165
Citations - 10417
Thomas Stuckey is an academic researcher from Cone Health. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 44, co-authored 158 publications receiving 9459 citations. Previous affiliations of Thomas Stuckey include Columbia University Medical Center & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
Gregg W. Stone,Cindy L. Grines,David A. Cox,Eulogio García,James E. Tcheng,John J. Griffin,Giulio Guagliumi,Thomas Stuckey,Mark Turco,John D. Carroll,Barry D. Rutherford,Alexandra J. Lansky +11 more
TL;DR: Stent implantation (with or without abciximab therapy) should be considered the routine reperfusion strategy in experienced centers and when used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further improve outcomes.
Journal ArticleDOI
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study
Gregg W. Stone,Bernhard Witzenbichler,Giora Weisz,Michael Rinaldi,Franz-Josef Neumann,D. Christopher Metzger,Timothy D. Henry,David A. Cox,Peter L. Duffy,Ernest L. Mazzaferri,Paul A. Gurbel,Ke Xu,Helen Parise,Ajay J. Kirtane,Bruce R. Brodie,Roxana Mehran,Thomas Stuckey +16 more
TL;DR: The findings from this study emphasise the counter-balancing effects of haemorrhagic and ischaemic complications after stent implantation, and suggest that safer drugs or tailored strategies for the use of more potent agents must be developed if the benefits of greater platelet inhibition in patients with cardiovascular disease are to be realised.
Journal ArticleDOI
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
Roxana Mehran,Usman Baber,Philippe Gabriel Steg,Cono Ariti,Giora Weisz,Bernhard Witzenbichler,Timothy D. Henry,Annapoorna Kini,Thomas Stuckey,David J. Cohen,Peter B. Berger,Ioannis Iakovou,George Dangas,Ron Waksman,David Antoniucci,Samantha Sartori,Mitchell W. Krucoff,James B. Hermiller,Fayaz A. Shawl,C. Michael Gibson,Alaide Chieffo,Maria Alu,David J. Moliterno,Antonio Colombo,Stuart J. Pocock +24 more
TL;DR: This study enrolled 5031 patients undergoing PCI with stent implantation in 15 clinical sites in the USA and Europe between July 1, 2009, and Dec 2, 2010 and examined the effect of DAPT cessation on major adverse events (MACE) and found those who discontinued had lower MACE risk.
Journal ArticleDOI
Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.
Amir Halkin,Mandeep Singh,Eugenia Nikolsky,Cindy L. Grines,James E. Tcheng,Eulogio García,David A. Cox,Mark Turco,Thomas Stuckey,Yingo Na,Alexandra J. Lansky,Bernard J. Gersh,William W. O'Neill,Roxana Mehran,Gregg W. Stone +14 more
TL;DR: In AMI patients treated with primary PCI, seven risk factors readily available at the time of intervention accurately predict short- and long-term mortality.
Journal ArticleDOI
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
Paul Sorajja,Bernard J. Gersh,David A. Cox,Michael G. McLaughlin,Peter Zimetbaum,Costantino O. Costantini,Thomas Stuckey,James E. Tcheng,Roxana Mehran,Alexandra J. Lansky,Cindy L. Grines,Gregg W. Stone +11 more
TL;DR: Patients with extensive CAD in vessels remote from the infarct-related artery have reduced reperfusion success and an adverse prognosis following primary PCI in AMI and future studies regarding the optimal treatment of patients with multivessel disease and AMI are warranted.